4Bandini G,Zuffa E,Rosti G,et al.Long-term outcome of adults with acute myelogenous leukemia:resules of a prospective,randomized study of chemotherapy with a minital follow-up of 7 years [J].Br J Haematol,1991,77(4):486-490.
5Bennett J M,Catovsky D,Daniel M T,et al.Prosed revised criteria for the classification of acute myeloid leukemia:a report of the French-American-British Cooperation Group[J].Ann Intern Med,1985,103(4):620-625.
6Brincker H,Christensen B E.Long-term survival and late relapses in acute leukemia in adults[J].Br J Harmatol,1990,74(2):156-160.
7Swansbury G T,Lawler S D,Alimena G,et al.Long-term survival in acute myelogenous leukemia:Asec ond follow-up of the Fourth International Workshop on chromosomes in leukemia[J].Cancer Genet Cytogenet,1994,73(1):1-7.
8Schiller G,Gajewski J,Nimer S,et al.A randomixed study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelologenous leukemia[J].Br J Haematol,1992,81(2):170-189.
9Buchner T,Hiddemann W,Wormann B,et al.Doublt induction strategy for acutcmyeloid leukemia:the effect of high-dose cylarabine with mitoxantrone instead of standard dose cyturadine with daunorubicin and 6-thioguanine:arandomized trial by the German Aml Cooperative Gnup[J].Blood,1999,93(12):4116-4124.
10Mandelli F,Annino L,Rotoli B.The GIMEMA ALL 0183 trial:analysis of 10-year follow-up[J].Br J Haematol,1996,92(3):665-672.
